Identification of indole-based activators of insulin degrading enzyme - Archive ouverte HAL Access content directly
Journal Articles European Journal of Medicinal Chemistry Year : 2021

Identification of indole-based activators of insulin degrading enzyme


Insulin degrading enzyme (IDE) is a zinc metalloprotease that cleaves numerous substrates among which amyloid-β and insulin. It has been linked through genetic studies to the risk of type-2 diabetes (T2D) or Alzheimer's disease (AD). Pharmacological activation of IDE is an attractive therapeutic strategy in AD. While IDE inhibition gave paradoxal activity in glucose homeostasis, recent studies, in particular in the liver suggest that IDE activators could be also of interest in diabetes. Here we describe the discovery of an original series of IDE activators by screening and structure-activity relationships. Early cellular studies show that hit 1 decreases glucose-stimulating insulin secretion. Docking studies revealed it has an unprecedented extended binding to the polyanion-binding site of IDE. These indole-based pharmacological tools are activators of both Aβ and insulin hydrolysis by IDE and could be helpful to explore the multiple roles of IDE.
Fichier principal
Vignette du fichier
S022352342100831X.pdf (1.32 Mo) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-03430475 , version 1 (08-01-2024)


Attribution - NonCommercial



Nicolas Kraupner, Chau Phi Dinh, Xiaoan Wen, Valérie Landry, Adrien Herledan, et al.. Identification of indole-based activators of insulin degrading enzyme. European Journal of Medicinal Chemistry, 2021, pp.113982. ⟨10.1016/j.ejmech.2021.113982⟩. ⟨hal-03430475⟩
56 View
3 Download



Gmail Facebook X LinkedIn More